NASDAQ:EVGN

Evogene Competitors

$4.37
+0.11 (+2.58 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.05
Now: $4.37
$4.40
50-Day Range
$4.26
MA: $5.06
$6.18
52-Week Range
$0.94
Now: $4.37
$10.24
Volume803,542 shs
Average Volume1.60 million shs
Market Capitalization$112.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43

Competitors

Evogene (NASDAQ:EVGN) Vs. NTR, SMG, MOS, CF, ICL, and AVD

Should you be buying EVGN stock or one of its competitors? Companies in the industry of "agricultural chemicals" are considered alternatives and competitors to Evogene, including Nutrien (NTR), The Scotts Miracle-Gro (SMG), The Mosaic (MOS), CF Industries (CF), ICL Group (ICL), and American Vanguard (AVD).

Evogene (NASDAQ:EVGN) and Nutrien (NYSE:NTR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Institutional and Insider Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 61.9% of Nutrien shares are held by institutional investors. 3.1% of Nutrien shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Evogene has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Nutrien has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Evogene and Nutrien's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evogene-2,649.69%-38.40%-32.43%
Nutrien0.47%4.19%1.98%

Analyst Recommendations

This is a summary of current ratings for Evogene and Nutrien, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evogene00103.00
Nutrien15612.54

Evogene currently has a consensus target price of $9.00, indicating a potential upside of 105.95%. Nutrien has a consensus target price of $56.4444, indicating a potential upside of 0.76%. Given Evogene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evogene is more favorable than Nutrien.

Earnings & Valuation

This table compares Evogene and Nutrien's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24
Nutrien$20.02 billion1.60$992 million$2.1725.82

Nutrien has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than Nutrien, indicating that it is currently the more affordable of the two stocks.

Summary

Nutrien beats Evogene on 11 of the 15 factors compared between the two stocks.

The Scotts Miracle-Gro (NYSE:SMG) and Evogene (NASDAQ:EVGN) are both basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

The Scotts Miracle-Gro has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Profitability

This table compares The Scotts Miracle-Gro and Evogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Scotts Miracle-Gro9.38%52.60%11.09%
Evogene-2,649.69%-38.40%-32.43%

Insider & Institutional Ownership

63.1% of The Scotts Miracle-Gro shares are owned by institutional investors. Comparatively, 33.0% of Evogene shares are owned by institutional investors. 27.2% of The Scotts Miracle-Gro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for The Scotts Miracle-Gro and Evogene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Scotts Miracle-Gro00313.25
Evogene00103.00

The Scotts Miracle-Gro currently has a consensus target price of $250.00, indicating a potential upside of 4.94%. Evogene has a consensus target price of $9.00, indicating a potential upside of 105.95%. Given Evogene's higher probable upside, analysts clearly believe Evogene is more favorable than The Scotts Miracle-Gro.

Valuation & Earnings

This table compares The Scotts Miracle-Gro and Evogene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Scotts Miracle-Gro$4.13 billion3.21$387.40 million$7.2432.90
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24

The Scotts Miracle-Gro has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than The Scotts Miracle-Gro, indicating that it is currently the more affordable of the two stocks.

Summary

The Scotts Miracle-Gro beats Evogene on 12 of the 15 factors compared between the two stocks.

Evogene (NASDAQ:EVGN) and The Mosaic (NYSE:MOS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 69.8% of The Mosaic shares are held by institutional investors. 0.5% of The Mosaic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Evogene and The Mosaic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evogene-2,649.69%-38.40%-32.43%
The Mosaic-13.05%N/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Evogene and The Mosaic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evogene00103.00
The Mosaic181002.47

Evogene presently has a consensus target price of $9.00, suggesting a potential upside of 105.95%. The Mosaic has a consensus target price of $27.9722, suggesting a potential downside of 16.40%. Given Evogene's stronger consensus rating and higher probable upside, analysts plainly believe Evogene is more favorable than The Mosaic.

Valuation & Earnings

This table compares Evogene and The Mosaic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24
The Mosaic$8.91 billion1.42$-1,067,400,000.00$0.19176.11

Evogene has higher earnings, but lower revenue than The Mosaic. Evogene is trading at a lower price-to-earnings ratio than The Mosaic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Evogene has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, The Mosaic has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Summary

The Mosaic beats Evogene on 9 of the 14 factors compared between the two stocks.

Evogene (NASDAQ:EVGN) and CF Industries (NYSE:CF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Valuation & Earnings

This table compares Evogene and CF Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24
CF Industries$4.59 billion2.21$493 million$1.9324.51

CF Industries has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than CF Industries, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 91.0% of CF Industries shares are held by institutional investors. 2.0% of CF Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Evogene and CF Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evogene00103.00
CF Industries17602.36

Evogene presently has a consensus price target of $9.00, indicating a potential upside of 105.95%. CF Industries has a consensus price target of $43.9167, indicating a potential downside of 7.17%. Given Evogene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evogene is more favorable than CF Industries.

Volatility and Risk

Evogene has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, CF Industries has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

Profitability

This table compares Evogene and CF Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evogene-2,649.69%-38.40%-32.43%
CF Industries7.00%5.14%2.34%

Summary

CF Industries beats Evogene on 10 of the 14 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Evogene (NASDAQ:EVGN) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Earnings & Valuation

This table compares ICL Group and Evogene's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion1.57$475 million$0.3717.43
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24

ICL Group has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than ICL Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.4% of ICL Group shares are owned by institutional investors. Comparatively, 33.0% of Evogene shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

ICL Group has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Profitability

This table compares ICL Group and Evogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group-0.12%5.99%2.56%
Evogene-2,649.69%-38.40%-32.43%

Analyst Ratings

This is a breakdown of recent ratings and target prices for ICL Group and Evogene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group02002.00
Evogene00103.00

ICL Group currently has a consensus price target of $5.75, suggesting a potential downside of 10.85%. Evogene has a consensus price target of $9.00, suggesting a potential upside of 105.95%. Given Evogene's stronger consensus rating and higher probable upside, analysts clearly believe Evogene is more favorable than ICL Group.

Summary

ICL Group beats Evogene on 7 of the 13 factors compared between the two stocks.

American Vanguard (NYSE:AVD) and Evogene (NASDAQ:EVGN) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Volatility & Risk

American Vanguard has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Institutional and Insider Ownership

76.5% of American Vanguard shares are held by institutional investors. Comparatively, 33.0% of Evogene shares are held by institutional investors. 5.3% of American Vanguard shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares American Vanguard and Evogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Vanguard2.40%3.16%1.61%
Evogene-2,649.69%-38.40%-32.43%

Analyst Ratings

This is a summary of recent ratings for American Vanguard and Evogene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Vanguard0000N/A
Evogene00103.00

Evogene has a consensus price target of $9.00, indicating a potential upside of 105.95%. Given Evogene's higher possible upside, analysts plainly believe Evogene is more favorable than American Vanguard.

Valuation & Earnings

This table compares American Vanguard and Evogene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Vanguard$468.19 million1.34$13.60 million$0.4644.13
Evogene$750,000.00150.04$-18,110,000.00($0.70)-6.24

American Vanguard has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than American Vanguard, indicating that it is currently the more affordable of the two stocks.

Summary

American Vanguard beats Evogene on 9 of the 13 factors compared between the two stocks.


Evogene Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nutrien logo
NTR
Nutrien
1.7$56.02+0.4%$31.94 billion$20.02 billion329.53Analyst Report
News Coverage
The Scotts Miracle-Gro logo
SMG
The Scotts Miracle-Gro
1.7$238.23+1.6%$13.27 billion$4.13 billion34.98Analyst Report
News Coverage
The Mosaic logo
MOS
The Mosaic
1.7$33.46+1.0%$12.68 billion$8.91 billion-11.66Analyst Upgrade
CF Industries logo
CF
CF Industries
2.0$47.31+0.1%$10.15 billion$4.59 billion35.84Analyst Report
Decrease in Short Interest
ICL Group logo
ICL
ICL Group
1.6$6.45+0.0%$8.26 billion$5.27 billion17.43
American Vanguard logo
AVD
American Vanguard
0.9$20.30+0.4%$627.31 million$468.19 million54.87News Coverage
CVR Partners logo
UAN
CVR Partners
0.4$46.20+0.0%$493.97 million$404.18 million-4.91Increase in Short Interest
Marrone Bio Innovations logo
MBII
Marrone Bio Innovations
1.3$1.71+3.5%$296.66 million$29.37 million-9.00Gap Down
Calyxt logo
CLXT
Calyxt
1.3$5.58+0.5%$207.33 million$7.30 million-4.20News Coverage
China Green Agriculture logo
CGA
China Green Agriculture
0.8$13.15+17.5%$83.50 million$249.24 million-0.49High Trading Volume
News Coverage
Gap Up
SenesTech logo
SNES
SenesTech
1.5$1.47+2.0%$7.50 million$140,000.00-0.19Increase in Short Interest
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.